These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37455217)

  • 1. Re: Ragheed Saoud, Varat Woranisarakul, Gladell P. Paner, et al. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.002.
    Gandaglia G; Barletta F; Briganti A; Montorsi F
    Eur Urol Focus; 2024 Jan; 10(1):205. PubMed ID: 37455217
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015.
    Cimadamore A; Lopez-Beltran A; Cheng L; Montironi R
    Eur Urol; 2023 Mar; 83(3):e84-e86. PubMed ID: 36517350
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Froehner M; Koch R; Thomas C
    Eur Urol; 2020 Aug; 78(2):e91. PubMed ID: 32381458
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Yash S. Khandwala, Simon John Christoph Soerensen, Shravan Morisetty, et al. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.10.010.
    Gravina C; Lombardo R; De Nunzio C
    Eur Urol Focus; 2023 Sep; 9(5):851-852. PubMed ID: 37005167
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007.
    Gandaglia G; Briganti A; Raggi D; Marandino L; Necchi A; Di Maio M; Montorsi F
    Eur Urol Focus; 2024 May; 10(3):497. PubMed ID: 36813620
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Giorgio Gandaglia, Alberto Briganti, Daniele Raggi, et al's Letter to the Editor re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007.
    Hoeh B; Chun FKH; Mandel P
    Eur Urol Focus; 2024 May; 10(3):498. PubMed ID: 36813619
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: K.R. Seetharam Bhat, Marcio Covas Moschovas, Marco Sandri, et al. Outcomes of Salvage Robot-assisted Radical Prostatectomy After Focal Ablation for Prostate Cancer in Comparison to Primary Robot-assisted Radical Prostatectomy: A Matched Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.10.005.
    Montorsi F; Stabile A; Gandaglia G; Briganti A
    Eur Urol Focus; 2022 Nov; 8(6):1868. PubMed ID: 35190294
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Carmen Gravina, Riccardo Lombardo, and Cosimo De Nunzio's Letter to the Editor re: Yash S. Khandwala, Simon John Christoph Soerensen, Shravan Morisetty, et al. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.10.010.
    Sonn G; Khandwala Y
    Eur Urol Focus; 2023 Sep; 9(5):822-823. PubMed ID: 37012086
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Sarah R. Ottenhof, Andrew Leone, Rosa S. Djajadiningrat, et al. Surgical and Oncological Outcomes in Patients After Vascularized Flap Reconstruction for Locoregionally Advanced Penile Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2018.02.002.
    Innocenti A; Melita D; Ghezzi S
    Eur Urol Focus; 2019 Nov; 5(6):1157. PubMed ID: 29674120
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Georges Mjaess, Alexandre Peltier, Jean-Baptiste Roche, et al. A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.008.
    Gravina C; Lombardo R; De Nunzio C
    Eur Urol Focus; 2024 Jan; 10(1):206-207. PubMed ID: 37541916
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002.
    Montorsi F; Larcher A; Capitanio U
    Eur Urol Focus; 2021 Mar; 7(2):406. PubMed ID: 31564640
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
    Vickers AJ
    Eur Urol; 2024 Sep; 86(3):e71. PubMed ID: 38797599
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
    Stroomberg HV; Brasso K; Røder A
    Eur Urol; 2024 Sep; 86(3):e64-e65. PubMed ID: 38749855
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Carmen Gravina, Riccardo Lombardo, and Cosimo De Nunzio's Letter to the Editor re: Georges Mjaess, Alexandre Peltier, Jean-Baptiste Roche, et al. A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.008.
    Mjaess G; Roumeguère T; Diamand R
    Eur Urol Focus; 2024 Jan; 10(1):75-76. PubMed ID: 37543515
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Cathrine Alvær Vinje, Maria Nyre Vigmostad, Svein R. Kjosavik, Henrik Grönberg, Bjørnar Gilje, Svein Skeie. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.08.009.
    Liu W; He Y; Yang B
    Eur Urol Focus; 2024 Mar; 10(2):244-245. PubMed ID: 38290858
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Britta Grüne, Fabian Siegel, Frank Waldbillig, et al. Long-term Reinterventions after Thulium Laser Enucleation of the Prostate: 12-Year Experience with more than 1000 Patients. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.12.006.
    Chang HC; Chung SD
    Eur Urol Focus; 2022 Nov; 8(6):1865. PubMed ID: 35337776
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to: Antonio Andrea Grosso, Agostino Tuccio, Matteo Salvi, Daniele Paganelli, Andrea Minervini, and Fabrizio Di Maida's Letter to the Editor re: Paolo Capogrosso, Eugenio Ventimiglia, Giuseppe Fallara, et al. Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.03.018.
    Capogrosso P; Ventimiglia E; Fallara G; Schifano N; Costa A; Candela L; Pellegrino F; Colandrea G; Cignoli D; De Angelis M; Belladelli F; Longoni M; Avesani G; Lanzaro F; Scattoni V; Dehò F; Salonia A; Briganti A; Montorsi F
    Eur Urol Focus; 2024 Jan; 10(1):207-208. PubMed ID: 37442724
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Hein V. Stroomberg, Signe Benzon Larsen, Torben Kjær Nielsen, J. Thomas Helgstrand, Klaus Brasso, Andreas Røder. Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.005.
    Gallo G; Lombardo R; De Nunzio C
    Eur Urol Oncol; 2024 Jun; 7(3):646-647. PubMed ID: 38290922
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Antonio Andrea Grosso, Agostino Tuccio, Matteo Salvi, Daniele Paganelli, Andrea Minervini, and Fabrizio Di Maida's Letter to the Editor re: Paolo Capogrosso, Eugenio Ventimiglia, Giuseppe Fallara, et al. Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve. Eur Urol Focus 2023;9:813-21. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.05.013.
    Lin YH; Chen ST; Juang HH
    Eur Urol Focus; 2024 Mar; 10(2):288-289. PubMed ID: 38272718
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017: Focus on Our Personal Recollections and Observations.
    Montironi R; Scarpelli M; Cimadamore A; Mikuz G
    Eur Urol Focus; 2022 May; 8(3):882-884. PubMed ID: 33994166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.